Exon 3 and exon/intron 4 were targeted with two sgRNAs using CRISPR/Cas9 technology, resulting in a 1958 bp deletion, encompassing most of exon 3 (which contains the ATG start site) and the entirety of intron 3 and exon 4. Immunoblots confirmed the absence of peptide expression from this allele in the brain.